LUNG CANCER

During a live event, Neal E. Ready, MD, and participants discussed what factors justify using PD-1 plus CTLA-4 inhibitor and chemotherapy in patients with non–small cell lung cancer in the PD-L1–low setting.

FDA accelerates approval of datopotamab deruxtecan for advanced EGFR-mutated NSCLC, offering new hope for previously treated patients.

Pembrolizumab combined with chemoradiation shows promising long-term efficacy and safety in treating advanced non-small cell lung cancer.

Combination therapy with savolitinib and osimertinib shows promising results in treating advanced NSCLC with EGFR mutations and MET overexpression.

During a live event, Neal E. Ready, MD, and participants discussed use of PD-L1 status in non–small cell lung cancer and compared the use of single agent vs doublet immunotherapy in the PD-L1–low setting.

Sevabertinib shows promise as a targeted therapy for HER2-mutant non-small cell lung cancer, addressing significant treatment gaps in this area.

Combination therapy of osimertinib and datopotamab deruxtecan shows promising efficacy in advanced NSCLC, warranting further phase 3 studies.

Taletrectinib emerges as a groundbreaking treatment for ROS1-mutant NSCLC, offering hope with its CNS activity and lower neurological side effects.

Jill Feldman discusses the background of the phase 2 COCOON trial in advanced non–small cell lung cancer with EGFR mutations.

Taletrectinib gains FDA approval as a groundbreaking treatment for ROS1-positive non-small cell lung cancer, offering hope for patients with CNS involvement.

Oncologists share their treatment preferences for patients with advanced NSCLC with EGFR mutations.

A recent study reveals promising outcomes for lung cancer patients who undergo rechallenge with different RET inhibitors after initial treatment failure.

A novel combination therapy shows promise for advanced lung cancer patients resistant to standard treatments, offering hope for improved survival rates.

Suresh S. Ramalingam, MD, FACP, FASCO, emphasizes the role of community oncologists in translating new advancements in lung cancer research into widespread patient benefit.

Neoadjuvant nivolumab plus chemotherapy significantly improves overall survival in resectable non-small cell lung cancer, marking a treatment breakthrough.

Benmelstobart alone or with anlotinib improved progression-free survival after chemoradiotherapy in unresectable stage III non–small cell lung cancer.

A molecular test identified patients with high-risk early lung cancer who significantly benefitted from adjuvant chemotherapy, improving survival without disease progression.

Christopher Danes, PhD, discusses how patient and caregiver priorities and concerns vary during the course of treatment for non–small cell lung cancer.

Christopher Danes, PhD, discusses a study exploring the differences in priorities for patients and their caregivers when undergoing treatment for non–small cell lung cancer.

David P. Carbone, MD, PhD, discusses the outcomes of the phase 3 CheckMate 9LA trial in non–small cell lung cancer based on treatment discontinuation.

Nicolas Girard, MD, PhD, discussed findings from the MARIPOSA and COCOON trials of amivantamab and lazertinib in EGFR+ NSCLC.

First-line cemiplimab showed improved survival vs chemotherapy in advanced NSCLC with brain metastases and PD-L1 ≥50% in EMPOWER-Lung 1.